VIR vs MNKD vs REGN vs UTHR

For growth investors, MannKind Corporation (MNKD) is the stronger pick with 22.

2% revenue growth year-over-year, versus -7. 6% for Vir Biotechnology, Inc. (VIR). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Vir Biotechnology, Inc. (VIR) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus MannKind Corporation at 177. 5x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 15. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: United Therapeutics Corporation wins at 1. 01x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a reasonable growth-adjusted valuation.

Over the past 5 years, United Therapeutics Corporation (UTHR) delivered a total return of +191.

3%, compared to -78. 4% for Vir Biotechnology, Inc. (VIR). Over 10 years, the gap is even starker: UTHR returned +410. 0% versus MNKD's -46. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), United Therapeutics Corporation (UTHR) is the lower-risk stock at 0.

19β versus Vir Biotechnology, Inc. 's 2. 05β — meaning VIR is approximately 972% more volatile than UTHR relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 24% for Vir Biotechnology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MannKind Corporation (MNKD) is pulling ahead at 22.

2% versus -7. 6% for Vir Biotechnology, Inc. (VIR). On earnings-per-share growth, the picture is similar: Vir Biotechnology, Inc. grew EPS 17. 5% year-over-year, compared to -79. 4% for MannKind Corporation. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

United Therapeutics Corporation (UTHR) is the more profitable company, earning 41.

9% net margin versus -638. 9% for Vir Biotechnology, Inc. — meaning it keeps 41. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTHR leads at 46. 9% versus -682. 7% for VIR. At the gross margin level — before operating expenses — UTHR leads at 87. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, United Therapeutics Corporation (UTHR) is the more undervalued stock at a PEG of 1. 01x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 15. 3x forward P/E versus 217. 8x for MannKind Corporation — 202. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VIR: 129. 7% to $21. 29.

In this comparison, REGN (0.

5% yield) pays a dividend. VIR, MNKD, UTHR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, United Therapeutics Corporation (UTHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), +410. 0% 10Y return). Vir Biotechnology, Inc. (VIR) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTHR: +410. 0%, VIR: -33. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VIR is a small-cap quality compounder stock; MNKD is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; UTHR is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.